Review
Open access
Oct 2026
Hypertension is a multifactorial cardiovascular disorder characterized by oxidative stress, endothelial dysfunction, chronic inflammation, mitochondrial impairment, and accelerated vascular aging, all of which contribute to hypertension-mediated target organ damage. Among the molecular pathways involved in these proces...
Sandra Budziak, M. Kloza, Przemysław Baranowski et al.
· Antioxidants · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Open access
Aug 2026
Elafibranor mitigates TGF-β1-driven cardiac fibrosis by suppressing fibroblast activation and ECM remodelling while promoting adaptive metabolic, redox, and bioenergetic responses, supporting balanced PPAR-α/δ activation as a potential therapeutic strategy for cardiac fibrosis.
M. Paw, L. Minder, A. Laimbacher et al.
· bioRxiv · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Open access
Aug 2026
Lanifibranor attenuates TGF-β1-driven cardiac fibrosis by combining antifibrotic effects with metabolic and functional improvements in human models.
M. Paw, L. Minder, A. Laimbacher et al.
· bioRxiv · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓